XM does not provide services to residents of the United States of America.
L
L

Lonza

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss trade surplus at CHF 8.063 bln in October

TABLE-Swiss trade surplus at CHF 8.063 bln in October November 19 (Reuters) - Switzerland ran a merchandise trade surplus of 8 .063 billion Swiss francs in October, the Federal Customs Office said on Tuesday. KEY FIGURES (millions of Swiss francs) October 2024 September 2024 Imports 19.681 17.620 Exports 27.745 22.562 Balance 8.063 4.942 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Lonza To Expand Bioconjugation In Visp With Two Additional Manufacturing Suites

BRIEF-Lonza To Expand Bioconjugation In Visp With Two Additional Manufacturing Suites Nov 12 (Reuters) - LONZA GROUP AG LONN.S : TO EXPAND BIOCONJUGATION IN VISP (CH) WITH TWO ADDITIONAL MANUFACTURING SUITES NEW CAPACITY WILL GENERATE APPROXIMATELY 200 NEW JOBS AND IS EXPECTED TO BE OPERATIONAL FROM 2028 Source text: ID:nEQ85bdK2a Further company c
L

Lonza Group AG Synaffix Collaborates With Bighat Biosciences On Development Of Machine Learning-Designed Adc

BRIEF-Lonza Group AG Synaffix Collaborates With Bighat Biosciences On Development Of Machine Learning-Designed Adc Nov 4 (Reuters) - Lonza Group AG LONN.S : LONZA GROUP AG: SYNAFFIX COLLABORATES WITH BIGHAT BIOSCIENCES ON DEVELOPMENT OF MACHINE LEARNING-DESIGNED ADC Source text: ID:nPreZQpDla Further company coverage: LONN.S ( Reuters.Briefs@thomso
L

Lonza Group Confirms Full Year Outlook

BRIEF-Lonza Group Confirms Full Year Outlook Oct 24 (Reuters) - LONZA GROUP AG LONN.S : OUTLOOK 2024 CONFIRMED: FLAT YEAR-ON-YEAR SALES IN CER AND A CORE EBITDA MARGIN OF HIGH 20S DEMAND REMAINS SOFT IN CAPSULES & HEALTH INGREDIENTS AND BIOSCIENCE BUSINESSES Q3 PERFORMANCE IN LINE Further company coverage: LONN.S (Gdansk Newsroom)
L

Lonza Extends Collaboration With Major Pharmaceutical Partner For Integrated Commercial Supply Of Antibody-Drug Conjugates

BRIEF-Lonza Extends Collaboration With Major Pharmaceutical Partner For Integrated Commercial Supply Of Antibody-Drug Conjugates Oct 22 (Reuters) - LONZA GROUP AG LONN.S : EXTENDS COLLABORATION WITH MAJOR PHARMACEUTICAL PARTNER FOR INTEGRATED COMMERCIAL SUPPLY OF ANTIBODY-DRUG CONJUGATES EXTENSION OF LONG-TERM COLLABORATION INCLUDES CONSTRUCTION OF
L

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.